UK Regulators Revoke Valneva's Chikungunya Vaccine License
Britain's MHRA pulled IXCHIQ's marketing authorization after a benefit-risk review, though no new safety signals were found.
British regulators have revoked the United Kingdom marketing authorization for Valneva's chikungunya vaccine IXCHIQ, the French specialty vaccine maker disclosed Tuesday, dealing a setback to the product's commercial reach in one of Europe's largest markets.
The Medicines and Healthcare products Regulatory Agency (MHRA) acted on a recommendation from the Commission on Human Medicines (CHM), which conducted a fresh benefit-risk assessment of IXCHIQ specifically for the traveler population. Valneva stressed that the withdrawal was rooted in a review of previously available safety data rather than any newly identified adverse event or safety signal.
Read more Hilco Real Estate Seeks Buyers for Detroit Rail-Served Industrial Sites →
The revocation is geographically contained. Valneva said the decision carries no implications for IXCHIQ's standing in the European Union, Canada, Brazil, or any other territory where the vaccine currently holds a marketing license, suggesting the company intends to defend and grow the product's footprint outside the UK.
Valneva, listed on both Nasdaq and Euronext Paris, developed IXCHIQ as a vaccine targeting chikungunya, a mosquito-borne viral disease that poses risk to international travelers visiting tropical and subtropical regions. The UK authorization's loss removes one potential revenue channel for the company in a market where travel vaccination demand can be significant.
The episode underscores the divergent regulatory pathways that can emerge post-Brexit, as UK authorities now operate independently of the European Medicines Agency framework, enabling country-specific benefit-risk conclusions that differ from those reached elsewhere. Continue reading at GlobeNewswire - Industry News on Financial Services.
